drugset / Trial / NCT05074940
Amivantamab in Adenoid Cystic Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Timeline
- Start
- 2022-08-05
- Primary completion
- 2026-03-02
- Completion
- 2028-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | 1050 mg | Intravenous |
| Subject | Amivantamab | Monoclonal antibody | 1400 mg | Intravenous |